Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

763 Features
Epilepsy

17 Jan 05

Epilepsy is a common condition in the UK, with an incidence of approximately 80 cases per 100,000 population per year, and a prevalence of 5–10 cases per 1000. Yet, despite this high prevalence, it remains a stigmatising condition, with occupational and social disadvantages imposed on the individual. Epilepsy is difficult to diagnose, requiring a detailed history, and is complex to manage.
Csf Medical Communications

Addressing the unmet need of diabetics with new generation non-insulin antidiabetics

17 Jan 05

It is estimated that there are more than 38 million people in the seven major markets with diabetes and this figure is set to rise to 50 million in 2012. However, despite this vast potential patient population, low diagnosis rates, the chronic nature of the disease, the need for combination therapy, the lack of an oral antidiabetic agent offering effective long-term therapy and the association of injectable therapies with poor patient compliance mean that a broad spectrum of unmet needs exists.
LeadDiscovery

Morgan Levy (formally E-Focus Resourcing) has rebranded.

13 Jan 05

Morgan Levy (formally E-Focus Resourcing) has pleasure in announcing that we have re-branded to Morgan Levy with effect from January 2005.
GARY M BRITNELL

SOCS1 silencing dramatically increases the anti-cancer efficacy of dendritic cell vaccines

04 Jan 05

The development of dendritic cell vaccines to fight cancer is an attractive therapeutic approach. Usually this strategy involves pre-pulsing dendritic cells with cancer antigen and maturing them ex vivo prior to administering them to patients. Limitations to this approach include the cumbersome nature of antigen loading and maturation and the limited immunogenicity of the cells. The company BioVEX have successfully developed viruses to load dendritic cells with antigen. Researchers from Baylor h
LeadDiscovery

Sorafenib offers hope in the battle for liver cancer survival

20 Dec 04

The outlook for hepatocellular carcinoma (HCC) sufferers is bleak - current medication has a five-year survival rate for those with liver cancer of less than 5% in the developed world and even lower in developing countries. However, patients in trials of a new drug called Sorafenib have seen their survival times double. Datamonitor's Dr Lorna Fern investigates...
Datamonitor

“Get behind Clean Hospital Summit” call as patient pressure rises

14 Dec 04

Britain’s hospital patients, led by Claire Rayner, today called for healthcare professionals to get behind the UK’s first ever Clean Hospitals Summit, planned for April 14-15, 2005.
Anna Harris/ Alan Murray

Developments in oncolytic viruses - An emerging approach to cancer therapeutics

13 Dec 04

This report introduces the emerging field of oncolytic viruses and the various benefits that oncolytic virology can offer in the treatment of cancer. Clinical data suggest that oncolytic viruses may offer therapeutic advantages over existing cancer therapies such as chemotherapy and radiation and may even act synergistically with these conventional approaches. This report evaluates preclinical and clinical data on oncolytic viruses that have entered the clinic.
LeadDiscovery

Japanese Pharma Prepares to Bounce Back

13 Dec 04

The Japanese pharmaceutical industry is facing a range of problems in competing with its foreign rivals. However, it has survived tough operating conditions before and there are signs that it will do so again.
Dr Faiz Kermani

Serevent warning focuses attention on the need for combination therapy

10 Dec 04

The recent announcement by the FDA's associate director for science and medicine that sales of GlaxoSmithKline's asthma drug Serevent should be restricted, or halted, led to an estimated 3.8% fall in the company's share price. However, Datamonitor's Laura Harris comments that, with Seretide accounting for the majority of GSK's asthma sales, the panic may be premature.
Datamonitor

Freedman takes snapshot of current marketing challenges at eyeforpharma workshop

09 Dec 04

Now, more than ever, pharma marketing operations are being required to demonstrate that they are adding value and delivering measurable return on investment. With this in mind, Freedman International surveyed delegates who attended the eyeforpharma ‘Marketing ROI for Pharma’ conference using a unique self-assessment tool to find out, “How do you fare in terms of the overall effectiveness of your marketing operations?”
Matt Adcock

Arava: the 'sixth drug' that may soon be under fire

08 Dec 04

At a recent hearing into the Vioxx affair, the FDA's Dr David Graham named five drugs that he considers too dangerous to be on the market. However, in his testimony, Dr Graham also cited Sanofi-Aventis' Arava as a drug he has recommended be withdrawn. Unlike the other five drugs, Arava has largely escaped the media spotlight, but there may yet be some tough questions asked about its safety.
Datamonitor

EmTech 5-6 April 2005

30 Nov 04

The conference will present the latest research and advances on new techniques in drug discovery. As well as presentations from some of the top authorities in the field, the exhibition will allow you to view the latest technologies from leading suppliers within the industry. An unmissable event for those wishing to keep abreast of new developments.
Natalie Bell

Free analysis: 'Barriers, best practices and measuring ROI for patient compliance programmes'

29 Nov 04

Unique intelligence from eyeforpharma: 'Barriers, best practices and measuring ROI for patient compliance programmes'
Izzy Wakeling

Tigecycline offers new hope in the battle against MRSA

26 Nov 04

Study data presented at a major recent conference has demonstrated that Wyeth's novel antibacterial tigecycline acts against drug-resistant pathogens in some serious bacterial infections, including MRSA. While Wyeth will have to work hard to establish tigecycline in this competitive area, its encouraging tolerability profile could give it a useful advantage over existing treatments.
Datamonitor

Influenza

19 Nov 04

Influenza is a global disease which imposes a huge medical and economic burden inevery country of the world. The UK is no exception with one caveat - the virus is probably monitored and tracked more in the UK than any other country around the globe. Over the years, GPs have played a leading role in estimating the quantitative impact of influenza. This started with the pioneering work of William Pickles in the Wensleydale villages and continued with Edgar Hope-Simpson in Cirencester.
CSF Medical

ADHD children not coming to attention of doctors

17 Nov 04

School can be a difficult place at the best of times, however for the 20 million plus children in the seven major pharmaceutical markets that suffer from attention deficit and hyperactivity disorder (ADHD), it can be especially troubling. This exacerbated by the fact that many patients aren't receiving the best available treatment, according to new research from Datamonitor.
Datamonitor

Hypertension and cardiovascular disease

09 Nov 04

Over the past 30 years, numerous clinical trials evaluating a variety of different classes of drugs have conclusively shown the benefit of blood pressure reduction in reducing the risk of strokes and cardiovascular mortality. Moreover, such trials have clearly demonstrated that blood pressure is unlikely to be controlled with a single drug and often two or more therapies are required to achieve blood pressure targets.
CSF Medical

Double trouble hits Altana respiratory pipeline

05 Nov 04

Altana has announced the delay of its US application for Daxas until late 2005 due to clinical trial enrolment taking longer than originally anticipated. The news will be of further concern to the company's investors, coming on the back of the recent announcement that another of its respiratory drugs, Alvesco, failed to win full FDA approval.
Datamonitor

The changing face of prostate cancer

04 Nov 04

Prostate cancer is the most common male malignancy in Western countries. Surgery and radiological procedures for localized prostate cancer offer the possibility for curative treatment. Prostate cancer also represents one of the most lucrative oncology indications for the pharmaceutical industry because drug-based treatment is often very effective at delaying disease progression, even in advanced disease, which encourages high-volume and long-term usage. The use of hormonal manipulation for advan
LeadDiscovery

An insight into hepatocellular carcinoma

29 Oct 04

Hepatocellular carcinoma is the fifth commonest cancer worldwide with about one million new cases diagnosed annually. It is estimated that the incidence of hepatocellular carcinoma in the seven major pharma markets will continue to rise over the next decade. There is no gold standard therapy - the market is characterized by high levels of unmet need, large patient potential and high commercial potential. To mark the publication of its new feature "Hepatocellular Carcinoma" LeadDiscovery's analys
LeadDiscovery

Cardiovascular risks of HRT confirmed

22 Oct 04

Treatment with combined estrogen/progestin doubles the risk of VTE in post-menopausal women and for obese women the risk is even higher, a recent study showed. However millions of women no longer taking HRT remain at risk of osteoporosis, which presents a huge market opportunity for non-hormonal classes in treating and preventing osteoporosis.
Datamonitor

Accelerating Drug Development and Limiting Failure of Phase I and II Clinical Trials

22 Oct 04

Limitations in the ability to optimize dose modification within the clinical trial setting represents a serious bottleneck in the drug development process. This barrier increases development time, causes the unnecessary early termination of valuable candidates and adds up to $300 million/drug in costs. Petra Biotek are set to knock down these barriers through their computer-based Cycle Dose Modification system. The positive impact that this technology is expected to have on the clinical developm
LeadDiscovery

Nexium GP resource provides real value

19 Oct 04

Healthcare professionals in the UK are already experiencing the benefits of being able to view this extensive product and disease-based resource online at a time and place that is convinient to them
Colin Williams

Going OTC in the USA

18 Oct 04

The OTC market has become highly competitive for pharmaceutical manufacturers, particularly in the US, which is the largest consumer society in the world. There have been a number of consolidations and acquisitions in the pharmaceutical sector to help companies boost their presence in the OTC field.
Dr Faiz Kermani

Don’t be scared of Assessment Centres

15 Oct 04

Recruitment is a very inexact science – the statistics in favour of making the right decision based on the traditional interview alone are horrifyingly low (the percentage is in single figures). This is a fact that has really only been acknowledged in recent years and, as a result, organisations have looked for ways to improve the success rate of their selection choices.
Lydia Holder

Peripheral arterial disease (PAD): A Significant Opportunity for Interventional Therapies

15 Oct 04

Peripheral arterial disease (PAD), caused by systemic atherosclerosis, is vastly underappreciated despite its abysmal mortality rates. With 5 and 10-year rates of 30% and 50% respectively mortality due to PAD is greater than that caused by coronary artery disease and stroke and is exceeded only by colorectal cancer. Better use of the pharmacological and interventional treatments available would dramatically improve the lives of the millions of PAD patients while at the same time ballooning the r
LeadDiscovery

Flu season begins but a vaccine shortage awaits

14 Oct 04

The recent government suspension of the manufacturing license for major flu vaccine maker Chiron in the UK has left many countries facing a severe shortage in flu vaccine supply for the 2004-05 season. In the light of previous vaccine provision difficulties, Datamonitor's Laura Harris argues that, in the longer term, cell culture vaccines could resolve the annual flu vaccine quandary...
Datamonitor

Life after Vioxx - $2.5 billion up for grabs?

11 Oct 04

Last week, Merck & Co sent shockwaves through the pharmaceutical market with the announcement that it had voluntarily withdrawn its blockbuster arthritis drug Vioxx. Datamonitor's Adele Schulz examines the likely impact of this event, for the remainder of 2004 and beyond, on both Merck and its rivals...
Datamonitor

HIV infection - changes in epidemiology driving R&D development and increased market value

07 Oct 04

The demographics of HIV patients are shifting, with the average age of those infected with HIV ever increasing due to longer life expectancy and higher survival rates. However, with increasingly complex infections and drug resistance developing in long term patients, novel medications and new combinations are now being launched to continue the fight...
LeadDiscovery

Therapeutic activity of Bayer's BAY 43-9006 in renal cell carcinoma

05 Oct 04

Renal cell carcinoma (RCC) is a niche cancer that accounts for 2-3% of all solid tumors in the major pharmaceutical markets. Approximately 30,000 patients are diagnosed with the disease each year in the US and 12,000 patients die of the disease annually. The market is currently dominated by the cytokines, but there is significant interest among physicians in the potential of anti-angiogenics, particularly so since renal cell carcinomas are known to be well vascularized. Bayer's BAY 43-9006 is a
LeadDiscovery

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.